Organization
Duke University Cancer Institute
6 abstracts
Abstract
Phase I trial of talimogene laherparepvec for the treatment of peritoneal surface malignancies (TEMPO).Org: Duke University Cancer Institute, Louisiana State University School of Medicine,
Abstract
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).Org: University of Texas Southwestern Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Cancer Institute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Wake Forest Baptist Health,
Abstract
Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer.Org: Duke University Cancer Institute, Seagen, Inc., Genesis Research, Winship Cancer Institute, Emory University School of Medicine,
Abstract
ctDNA detection in patients with brain metastases arising from solid tumors.Org: Duke University Medical Center, Department of Biostatistics & Bioinformatics & CALGB Statistical Center, Duke Cancer Institute, Duke University Cancer Institute, Dana-Farber Cancer Institute,
Abstract
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.Org: Dana-Farber Cancer Institute, Carolina Urologic Research Center, Bayer HealthCare Pharmaceuticals Inc., Bayer Consumer Care AG, Bayer PLC,
Abstract
Comprehensive myeloid-derived suppressor cell (MDSC) immunophenotyping and functional assessment in chimeric antigen receptor (CAR) T therapy.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Duke University Cancer Institute,